Study of ABSK021 for chronic graft-versus-host disease
Part of Immune system & allergy clinical trials.
This trial tests an experimental drug (ABSK021) for people with chronic graft-versus-host disease (cGvHD) after a stem cell transplant. It may help if other treatments haven't worked well enough.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have had a stem cell or bone marrow transplant from a donor.
- You have already tried at least one treatment for your chronic graft-versus-host disease (cGvHD).
- If you are on steroids or other immune-suppressing drugs, your dose has been stable for at least 2 weeks.
- You have not had more than 5 prior treatments for cGvHD.
- You do not have an active infection or a history of reaction to the study drug's ingredients.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, BPC2001, to see if it can prevent graft-versus-host disease (a common complication where donor cells attack the patient's body) in people receiving a half-matched stem cell transplant from a family donor. It may be an option for adults with certain blood cancers who are planning their first transplant.
This study tests a new cell therapy called GT729 for people with chronic graft-versus-host disease (cGVHD) that hasn't improved with at least two previous treatments. The therapy is given as an injection and aims to help control the immune system reaction that causes cGVHD.
This trial tests an experimental capsule (AC-003) for people with graft-versus-host disease (aGVHD) after a stem cell transplant, whose aGVHD did not get better with steroids. The goal is to see if it can help control the condition.
This study is testing an investigational cell therapy called NCR102 for people who have severe graft-versus-host disease (a complication after a stem cell transplant) that mainly affects the gut and has not responded to standard treatments. The goal is to see if this new approach is safe and can help control the disease.
This study tests an oral medication called belumosudil for people who have chronic graft-versus-host disease (cGVHD) after a stem cell transplant. It aims to see how safe the drug is. You may qualify if you have already tried at least two other treatments and are currently on a stable steroid dose.
This study tests a new drug called axatilimab for people with a specific type of chronic graft-versus-host disease (cGVHD) that causes hardening or thickening of the skin or joints. cGVHD is a complication after a stem cell transplant where the donor's immune cells attack your body. The study aims to see if axatilimab can improve these sclerotic symptoms. If you have this condition and it was recently diagnosed (within the last year), you might qualify to participate.
Hear when a new cGVHD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.